Prevention van PC-AKI
This module consists of seven submodules.
Verantwoording
Autorisatiedatum en geldigheid
Laatst beoordeeld : 01-11-2017
Laatst geautoriseerd : 01-11-2017
Geplande herbeoordeling : 01-01-2024
Validity
The board of the Radiological Society of the Netherlands will determine at the latest in 2023 if this guideline (per module) is still valid and applicable. If necessary, a new working group will be formed to revise the guideline. The validity of a guideline can be shorter than 5 years, if new scientific or healthcare structure developments arise, that could be seen as a reason to commence revisions. The Radiological Society of the Netherlands is considered the keeper of this guideline and thus primarily responsible for the actuality of the guideline. The other scientific societies that have participated in the guideline development share the responsibility to inform the primarily responsible scientific society about relevant developments in their field.
Initiative
Radiological Society of the Netherlands
Authorization
The guideline is submitted for authorization to:
- Association of Surgeons of the Netherlands
- Dutch Association of Urology
- Dutch Federation of Nephrology
- Dutch Society Medical Imaging and Radiotherapy
- Dutch Society of Intensive Care
- Netherlands Association of Internal Medici
- Netherlands Society for Clinical Chemistry and Laboratory Medicine
- Netherlands Society of Cardiology
- Netherlands Society of Emergency Physicians
- Radiological Society of the Netherlands
Algemene gegevens
General Information
The guideline development was assisted by the Knowledge Institute of Medical Specialists (https://www.kennisinstituut.nl) and was financed by the Quality Funds for Medical Specialists (Kwaliteitsgelden Medisch Specialisten: SKMS).
Doel en doelgroep
Goal of the current guideline
The aim of the Part 1 of Safe Use of Iodine-containing Contrast Media guidelines is to critically review the present recent evidence with the above trend in mind, and try to formulate new practical guidelines for all hospital physicians to provide the safe use of contrast media in diagnostic and interventional studies. The ultimate goal of this guideline is to increase the quality of care, by providing efficient and expedient healthcare to the specific patient populations that may benefit from this healthcare and simultaneously guard patients from ineffective care. Furthermore, such a guideline should ideally be able to save money and reduce day-hospital waiting lists.
Users of this guideline
This guideline is intended for all hospital physicians that request or perform diagnostic or interventional radiologic or cardiologic studies for their patients in which CM are involved.
Samenstelling werkgroep
Working group members
A multidisciplinary working group was formed for the development of the guideline in 2014. The working group consisted of representatives from all relevant medical specialization fields that are involved with intravascular contrast administration.
All working group members have been officially delegated for participation in the working group by their scientific societies. The working group has developed a guideline in the period from October 2014 until July 2017.
The working group is responsible for the complete text of this guideline.
Working group
Cobbaert C., clinical chemist, Leiden University Medical Centre (member of advisory board from September 2015)
Danse P., interventional cardiologist, Rijnstate Hospital, Arnhem
Dekker H.M., radiologist, Radboud University Medical Centre, Nijmegen
Geenen R.W.F., radiologist, Noordwest Ziekenhuisgroep (NWZ), Alkmaar/Den Helder
Hoogeveen E.K., nephrologist, Jeroen Bosch Hospital, ‘s-Hertogenbosch
Kooiman J., research physician, Leiden University Medical Centre, Leiden
Oudemans - van Straaten H.M., internist-intensive care specialist, Free University Medical Centre, Amsterdam
Pels Rijcken T.H., interventional radiologist, Tergooi, Hilversum
Sijpkens Y.W.J., nephrologist, Haaglanden Medical Centre, The Hague
Vainas T., vascular surgeon, University Medical Centre Groningen (until September 2015)
van den Meiracker A.H., internist-vascular medicine, Erasmus Medical Centre, Rotterdam
van der Molen A.J., radiologist, Leiden University Medical Centre, Leiden (chairman)
Wikkeling O.R.M., vascular surgeon, Heelkunde Friesland Groep, location: Nij Smellinghe Hospital, Drachten (from September 2015)
Advisory board
Demir A.Y., clinical chemist, Meander Medical Center, Amersfoort, (member of working group until September 2015)
Hubbers R., patient representative, Dutch Kidney Patient Association
Mazel J., urologist, Spaarne Gasthuis, Haarlem
Moos S., resident in Radiology, HAGA Hospital, The Hague
Prantl K., Coordinator Quality & Research, Dutch Kidney Patient Association
van den Wijngaard J., resident in Clinical Chemistry, Leiden University Medical Center
Methodological support
Boschman J., advisor, Knowledge Institute of Medical Specialists (from May 2017)
Burger K., senior advisor, Knowledge Institute of Medical Specialists (until March 2015)
Harmsen W., advisor, Knowledge Institute of Medical Specialists (from May 2017)
Mostovaya I.M., advisor, Knowledge Institute of Medical Specialists
Persoon S., advisor, Knowledge Institute of Medical Specialists (March 2016 – September 2016)
van Enst A., senior advisor, Knowledge Institute of Medical Specialists (from January 2017)
Belangenverklaringen
Conflicts of interest
The working group members have provided written statements about (financially supported) relations with commercial companies, organisations or institutions that are related to the subject matter of the guideline. Furthermore, inquiries have been made regarding personal financial interests, interests due to personal relationships, interests related to reputation management, interest related to externally financed research and interests related to knowledge valorisation. The statements on conflict of interest can be requested at the administrative office of the Knowledge Institute of Medical Specialists and are summarised below.
Member |
Function |
Other offices |
Personal financial interests |
Personal relationships |
Reputation management |
Externally financed research |
Knowledge-valorisation |
Other potential conflicts of interest |
Signed |
Workgroup |
|||||||||
Burger |
Advisor, Knowledge Institute of Medical Specialists |
None |
None |
None |
None |
None |
None |
None |
Yes |
Cobbaert |
Member, physician clinical chemistry |
Head of clinical chemistry department in Leiden LUMC. Tutor for post-academic training of clinical chemists, coordinator/host for the Leiden region Member of several working groups within the Dutch Society for Clinical Chemistry and member of several international working groups for clinical chemistry |
None |
None |
Member of several working groups within the Dutch Society for Clinical Chemistry and member of several international working groups for clinical chemistry |
None |
None |
None |
Yes |
Danse |
Member, cardiologist |
Board member committee of Quality, Dutch society for Cardiology (unpaid) Board member Conference committee DRES (unpaid) |
None |
None |
None |
None |
None |
None |
Yes |
Dekker |
Member, radiologist |
None |
None |
None |
None |
None |
None |
None |
Yes |
Geenen |
Member, radiologist |
Member Contrast Media Safety Committee of the European Society of Urogenital Radiology (unpaid, meetings are partially funded by CM industry))) |
None |
None |
None |
None |
None |
Has been a public speaker during symposia organised by GE Healthcare about contrast agents (most recently in June 2014) |
Yes |
Hoogeveen |
Member, nephrologist |
Member of Guideline Committee of Dutch Federation of Nephrology |
None |
None |
Member of Guideline Committee of Dutch Society for Nephrology |
Grant from the Dutch Kidney Foundation to study effect of fish oil on kidney function in post-MI patients |
None |
None |
Yes |
Kooiman |
Member, research physician |
Resident in department of gynaecology & obstetrics |
None |
None |
None |
None |
None |
None |
Yes |
Mostovaya |
Advisor, Knowledge Institute of Medical Specialists |
None |
None |
None |
None |
None |
None |
None |
Yes |
Oudemans – van Straaten |
Member, intensive care medical specialist Professor Intensive Care |
none |
None |
None |
None |
None |
None |
None |
Yes |
Pels Rijcken |
Member, interventional radiologist |
None |
None |
None |
None |
None |
None |
None |
Yes |
Sijpkens |
Member, nephrologist |
None |
None |
None |
None |
None |
None |
None |
Yes |
Vainas |
Member, vascular surgeon |
None |
None |
None |
None |
None |
None |
None |
Yes |
Van den Meiracker |
Member, internist vascular medicine |
None |
None |
None |
None |
None |
None |
None |
Yes |
Van der Molen |
Chairman, radiologist |
Member Contrast Media Safety Committee of the European Society of Urogenital Radiology (unpaid,CMSC meetings are partially funded by CM industry)) |
None |
None |
Secretary section of Abdominal Radiology; Radiological Society of the Netherlands (until spring of 2015) |
None |
None |
Receives Royalties for books: Contrast Media Safety, ESUR guidelines, 3rd ed. Springer, 2015 Received speaker fees for lectures on CM safety by GE Healthcare, Guerbet, Bayer Healthcare and Bracco Imaging (2015-2016) |
Yes |
Wikkeling |
Member, vascular surgeon |
None |
None |
None |
None |
None |
None |
None |
Yes |
Advisory Board |
|||||||||
Demir |
Member, physician clinical chemistry |
None |
None |
None |
None |
None |
None |
None |
Yes |
Hubbers |
Member, patient’s representative, Dutch Society of Kidney Patients |
None |
None |
None |
None |
None |
None |
None |
Yes |
Mazel |
Member, urologist |
None |
None |
None |
None |
None |
None |
None |
Yes |
Prantl |
Member, policy maker, Dutch Society of Kidney Patients |
None |
None |
None |
None |
None |
None |
None |
Yes |
Van den Wijngaard |
Member, resident clinical chemistry |
Reviewer for several journals (such as American Journal of Physiology) |
None |
None |
None |
None |
None |
None |
Yes |
Inbreng patiëntenperspectief
Patients’ perspective was represented, firstly by membership and involvement in the advisory board of a policy maker and a patients’ representative from the Dutch Kidney Patient Association. Furthermore, an online survey was organized by the Dutch Kidney Patient Association about the subject matter of the guideline. A summary of the results of this survey has been discussed during a working group meeting at the beginning of the guideline development process. Subjects that were deemed relevant by patients were included in the outline of the guideline. The concept guideline has also been submitted for feedback during the comment process to the Dutch Patient and Consumer Federation, who have reported their feedback through the Dutch Kidney Patient Association.
Methode ontwikkeling
Evidence based
Implementatie
In the different phases of guideline development, the implementation of the guideline and the practical enforceability of the guideline were taken into account. The factors that could facilitate or hinder the introduction of the guideline in clinical practice have been explicitly considered. The implementation plan can be found with the Related Products. Furthermore, quality indicators were developed to enhance the implementation of the guideline. The indicators can also be found with the Related Products.
Werkwijze
AGREE
This guideline has been developed conforming to the requirements of the report of Guidelines for Medical Specialists 2.0; the advisory committee of the Quality Counsel. This report is based on the AGREE II instrument (Appraisal of Guidelines for Research & Evaluation II) (www.agreetrust.org), a broadly accepted instrument in the international community and on the national quality standards for guidelines: “Guidelines for guidelines” (www.zorginstituutnederland.nl).
Identification of subject matter
During the initial phase of the guideline development, the chairman, working group and the advisor inventory the relevant subject matter for the guideline. Furthermore, an Invitational Conference was organized, where additional relevant subjects were suggested by the Dutch Kidney Patient Association, Dutch Society for Emergency Physicians, and Dutch Society for Urology. A report of this meeting can be found in Related Products.
Clinical questions and outcomes
During the initial phase of guideline development, the chairman, working group and advisor identified relevant subject matter for the guideline. Furthermore, input was acquired for the outline of the guideline during an Invitational Conference. The working group then formulated definitive clinical questions and defined relevant outcome measures (both beneficial land harmful effects). The working group rated the outcome measures as critical, important and not important. Furthermore, where applicable, the working group defined relevant clinical differences.
Strategy for search and selection of literature
For the separate clinical questions, specific search terms were formulated and published scientific articles were sought after in (several) electronic databases. Furthermore, studies were looked for by cross-referencing other included studies. The studies with potentially the highest quality of research were looked for first. The working group members selected literature in pairs (independently of each other) based on title and abstract. A second selection was performed based on full text. The databases search terms and selection criteria are described in the modules containing the clinical questions.
Quality assessment of individual studies
Individual studies were systematically assessed, based on methodological quality criteria that were determined prior to the search, so that risk of bias could be estimated. This is described in the “risk of bias” tables.
Summary of literature
The relevant research findings of all selected articles are shown in evidence tables. The most important findings in literature are described in literature summaries. When there were enough similarities between studies, the study data were pooled.
Grading the strength of scientific evidence
A) For intervention questions
The strength of the conclusions of the scientific publications was determined using the GRADE-method. GRADE stands for Grading Recommendations Assessment, Development and Evaluation (see http://www.gradeworkinggroup.org/) (Atkins, 2004).
GRADE defines four gradations for the quality of scientific evidence: high, moderate, low or very low. These gradations provide information about the amount of certainty about the literature conclusions. (http://www.guidelinedevelopment.org/handbook/).
B) For diagnostic, etiological, prognostic or adverse effect questions, the GRADE-methodology cannot (yet) be applied. The quality of evidence of the conclusion is determined by the EBRO method (van Everdingen, 2004)
Formulating conclusion
For diagnostic, etiological, prognostic or adverse effect questions, the evidence was summarized in one or more conclusions, and the level of the most relevant evidence was reported. For intervention questions, the conclusion was drawn based on the body of evidence (not one or several articles). The working groups weighed the beneficial and harmful effects of the intervention.
Considerations
Aspects such as expertise of working group members, patient preferences, costs, availability of facilities, and organization of healthcare aspects are important to consider when formulating a recommendation. These aspects were discussed in the paragraph Considerations.
Formulating recommendations
The recommendations answer the clinical question and were based on the available scientific evidence and the most relevant considerations.
Constraints (organization of healthcare)
During the development of the outline of the guideline and the rest of the guideline development process, the organization of healthcare was explicitly taken into account. Constraints that were relevant for certain clinical questions were discussed in the Consideration paragraphs of those clinical questions. The comprehensive and additional aspects of the organization of healthcare were discussed in a separate chapter.
Development of quality indicators
Internal (meant for use by scientific society or its members) quality indicators are developed simultaneously with the guideline. Furthermore, existing indicators on this subject were critically appraised; and the working group produces an advice about such indicators. Additional information on the development of quality indicators is available by contacting the Knowledge Institute for Medical Specialists. (secretariaat@kennisinstituut.nl).
Knowledge Gaps
During the development of the guideline, a systematic literature search was performed the results of which help to answer the clinical questions. For each clinical question the working group determined if additional scientific research on this subject was desirable. An overview of recommendations for further research is available in the appendix Knowledge Gaps.
Comment- and authorisation phase
The concept guideline was subjected to commentaries by the involved scientific societies. The commentaries were collected and discussed with the working group. The feedback was used to improve the guideline; afterwards the working group made the guideline definitive. The final version of the guideline was offered for authorization to the involved scientific societies, and was authorized.
References
Atkins D, Eccles M, Flottorp S, et al. GRADE Working Group. Systems for grading the quality of evidence and the strength of recommendations I: critical appraisal of existing approaches The GRADE Working Group. BMC Health Serv Res. 2004 Dec 22;4(1):38.
Van Everdingen JJE, Burgers JS, Assendelft WJJ, et al. Evidence-based richtlijnontwikkeling. Bohn Stafleu van Loghum. Houten, 2004